125 related articles for article (PubMed ID: 31104762)
1. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR
Zhang Y; Zeng X; Deng H; Ma F; Peng Y; Yi L; Tan C; Peng L
Clin Ther; 2019 Jun; 41(6):1175-1185. PubMed ID: 31104762
[TBL] [Abstract][Full Text] [Related]
2. Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?
Albright RH; Joseph RM; Wukich DK; Armstrong DG; Fleischer AE
Clin Orthop Relat Res; 2020 Dec; 478(12):2869-2888. PubMed ID: 32694315
[TBL] [Abstract][Full Text] [Related]
3. Is circulating tumor cell count-driven cost-effective for first-line therapy choice in HR+/HER2- metastatic breast cancer in the United States?
Lin H; Wu W; Lou X; Wang Y; Sun H; Cai J; Liu S; Wei X
Breast; 2024 Apr; 74():103680. PubMed ID: 38359563
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2- advanced breast cancer.
Hong J; Chen T; Ouyang L; Du N; Li A; Zhou Z; Zhang H; Xia Z; Meng J
Expert Rev Pharmacoecon Outcomes Res; 2024 Apr; 24(4):559-566. PubMed ID: 38470447
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Yang J; Han J; Tian M; Tian K; Liao W; Yan X
Cancer Manag Res; 2020; 12():12905-12913. PubMed ID: 33364838
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom.
Suri G; Chandiwana D; Lee A; Mistry R
J Health Econ Outcomes Res; 2019; 6(2):20-31. PubMed ID: 32685577
[TBL] [Abstract][Full Text] [Related]
7. Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER2 Negative Metastatic Breast Cancer: A Commentary.
Babcock A; Ali AA; Balkrishnan R; Montero A; Diaby V
J Manag Care Spec Pharm; 2020 Jul; 26(7):826-831. PubMed ID: 32584682
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam.
Nguyen AQ; Tran OTM; Nguyen PK; Nguyen HT
PLoS One; 2024; 19(3):e0300474. PubMed ID: 38489305
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand.
Sriphoosanaphan S; Pantumongkol W; Kulpeng W; Charonpongsuntorn C; Tanwandee T; Sukeepaisarnjaroen W; Sobhonslidsuk A; Tangkijvanich P
PLoS One; 2024; 19(3):e0300327. PubMed ID: 38512900
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of risk-based breast cancer screening programme, China.
Sun L; Legood R; Sadique Z; Dos-Santos-Silva I; Yang L
Bull World Health Organ; 2018 Aug; 96(8):568-577. PubMed ID: 30104797
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of a population-based AAA screening program for men over 65 years old in Iran.
Daroudi R; Shafe O; Moosavi J; Salimi J; Bayazidi Y; Zafarghandi MR; Maleki M; Moini M; Farshidmehr P; Sadeghipour P
Cost Eff Resour Alloc; 2021 May; 19(1):29. PubMed ID: 33985531
[TBL] [Abstract][Full Text] [Related]
12. The combination use of inclisiran and statins versus statins alone in the treatment of dyslipidemia in mainland China: a cost-effectiveness analysis.
Zhou W; Liang Z; Lou X; Wang N; Liu X; Li R; Pai P
Front Pharmacol; 2024; 15():1283922. PubMed ID: 38469404
[No Abstract] [Full Text] [Related]
13. Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer.
Cameron DA; Camidge DR; Oyee J; Hirsch M
Br J Cancer; 2008 Dec; 99(12):1984-90. PubMed ID: 19018261
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore.
Lim EH; Lim A; Khara JS; Cheong J; Fong J; Sivanesan S; Griffiths M; New E; Lee SC
Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):413-426. PubMed ID: 38289042
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysis.
Wu Y; Hu S; Liu X; Chen Y; Luan J; Wang S
Cost Eff Resour Alloc; 2024 Apr; 22(1):32. PubMed ID: 38659013
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102.
Saber W; Bansal A; Li L; Scott BL; Sangaralingham LR; Thao V; Roth JA; Wright W; Steuten LMG; Pidala JA; Mishra A; Maziarz RT; Westervelt P; McGuirk JP; Cutler C; Nakamura R; Ramsey SD
JCO Oncol Pract; 2024 Apr; 20(4):572-580. PubMed ID: 38261970
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of breast cancer screening using mammography in Vietnamese women.
Nguyen CP; Adang EMM
PLoS One; 2018; 13(3):e0194996. PubMed ID: 29579131
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective.
Machado M; Einarson TR
Breast Cancer (Dove Med Press); 2012; 4():173-82. PubMed ID: 24367204
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China.
Wei J; Xu K; Lin Y; Liu Q; Zhou C; Zhang P; Ma R; Zhang M; Zhang L; Li X
Int J Clin Pharm; 2024 May; ():. PubMed ID: 38814514
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of a Workplace-Based Hypertension Management Program in Real-World Practice in the Kailuan Study.
Zhou YF; Chen S; Chen JX; Chen S; Wang G; Pan XF; Wu S; Pan A
J Am Heart Assoc; 2024 Apr; 13(8):e031578. PubMed ID: 38563379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
